Luca Issi
Stock Analyst at RBC Capital
(1.28)
# 3,466
Out of 4,876 analysts
199
Total ratings
35.09%
Success rate
-15.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $5 → $4 | $2.47 | +61.94% | 8 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $1.20 | +733.33% | 9 | May 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $21 → $18 | $18.40 | -2.17% | 7 | May 8, 2025 | |
| MRNA Moderna | Maintains: Sector Perform | $32 → $28 | $27.54 | +1.67% | 14 | May 2, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $205 → $210 | $173.17 | +21.27% | 2 | May 2, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $24 → $20 | $4.17 | +380.19% | 5 | Mar 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $310 → $330 | $318.25 | +3.69% | 27 | Mar 21, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $105 → $95 | $12.34 | +669.85% | 7 | Mar 19, 2025 | |
| SGMO Sangamo Therapeutics | Reiterates: Sector Perform | $2 | $0.56 | +258.87% | 6 | Mar 18, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | $17 | $9.46 | +79.70% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $6.68 | +94.61% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $15 | $11.26 | +33.27% | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $4.07 | +759.95% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $17.14 | +51.69% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $39.78 | +75.97% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $54.10 | +29.39% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $53 → $48 | $46.70 | +2.78% | 13 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $16.07 | +161.36% | 8 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $14.23 | +68.66% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $33.83 | +68.49% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $8.75 | +242.86% | 9 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $29.83 | +124.61% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $10.05 | +347.76% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.12 | +88.68% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $37.13 | +107.38% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $7.03 | +113.37% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $9.61 | +461.91% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.35 | +937.04% | 5 | Aug 7, 2024 |
Adverum Biotechnologies
May 15, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.47
Upside: +61.94%
Allogene Therapeutics
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.20
Upside: +733.33%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $18.40
Upside: -2.17%
Moderna
May 2, 2025
Maintains: Sector Perform
Price Target: $32 → $28
Current: $27.54
Upside: +1.67%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $205 → $210
Current: $173.17
Upside: +21.27%
Lexeo Therapeutics
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $4.17
Upside: +380.19%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Outperform
Price Target: $310 → $330
Current: $318.25
Upside: +3.69%
Korro Bio
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $12.34
Upside: +669.85%
Sangamo Therapeutics
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.56
Upside: +258.87%
Ocular Therapeutix
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $9.46
Upside: +79.70%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $6.68
Upside: +94.61%
Mar 4, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $11.26
Upside: +33.27%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $4.07
Upside: +759.95%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $17.14
Upside: +51.69%
Feb 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $39.78
Upside: +75.97%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $54.10
Upside: +29.39%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $53 → $48
Current: $46.70
Upside: +2.78%
Feb 11, 2025
Reiterates: Outperform
Price Target: $42
Current: $16.07
Upside: +161.36%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $14.23
Upside: +68.66%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $33.83
Upside: +68.49%
Jan 21, 2025
Reiterates: Outperform
Price Target: $30
Current: $8.75
Upside: +242.86%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $29.83
Upside: +124.61%
Jan 14, 2025
Reiterates: Outperform
Price Target: $45
Current: $10.05
Upside: +347.76%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.12
Upside: +88.68%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $37.13
Upside: +107.38%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $7.03
Upside: +113.37%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $9.61
Upside: +461.91%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.35
Upside: +937.04%